BOSTON, MA, October 29, 2025

美国马萨诸塞州波士顿，2025年10月29日

– Tiziana Life Sciences, Ltd. (Nasdaq:

– Tiziana Life Sciences, Ltd. (纳斯达克:

TLSA

TLSA

) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation as a presenting company at BIO-Europe 2025. The event, Europe’s premier life sciences partnering conference, will take place November 3–5, 2025, at the Vienna Exhibition and Congress Center (Messe Wien) in Vienna, Austria..

）（“Tiziana”或“公司”），一家开发生物免疫调节疗法的生物技术公司，其主要开发候选药物是鼻内给药的foralumab，一种全人源抗CD3单克隆抗体，今天宣布将作为演讲公司参加BIO-Europe 2025。该活动是欧洲顶尖的生命科学合作会议，将于2025年11月3日至5日在奥地利维也纳的维也纳展览和会议中心（Messe Wien）举行。

Tiziana’s management team, led by CEO Ivor Elrifi, will also engage in one-on-one partnering meetings with leading biopharma executives and investors. The Company’s presentation will focus on its innovative nasal delivery platform and lead candidate, intranasal foralumab—the only fully human anti-CD3 monoclonal antibody in clinical development.

蒂齐亚娜的管理团队由首席执行官伊沃·埃尔里菲带领，还将与领先的生物制药高管和投资者进行一对一的合作会议。公司的演讲将集中在其创新的鼻腔递送平台和主要候选药物——鼻腔给药的foralumab，这是目前临床开发中唯一的全人源抗CD3单克隆抗体。

This proprietary approach aims to enhance efficacy, safety, and tolerability over traditional intravenous methods, targeting neuroinflammatory and neurodegenerative diseases such as non-active secondary progressive multiple sclerosis (na-SPMS), Multiple System Atrophy (MSA), and early Alzheimer’s disease..

这种方法旨在增强疗效、安全性和耐受性，超越传统的静脉注射方法，针对神经炎症和神经退行性疾病，如非活动性继发进展型多发性硬化症（na-SPMS）、多系统萎缩（MSA）和早期阿尔茨海默病。

“We are excited to showcase Tiziana’s progress at BIO-Europe 2025, a pivotal forum for forging strategic partnerships that can accelerate our pipeline toward commercialization,” said Ivor Elrifi, CEO of Tiziana Life Sciences. “Building on our ongoing Phase 2 clinical trials in na-SPMS and MSA, we are about to commence Phase 2 studies in early Alzheimer’s disease and in amyotrophic lateral sclerosis (“ALS”).

“我们很高兴在2025年BIO-Europe展示Tiziana的进展，这是一个促成战略合作伙伴关系的关键平台，可以加速我们的产品线走向商业化，”Tiziana生命科学公司首席执行官Ivor Elrifi表示。“基于我们在na-SPMS和MSA领域正在进行的二期临床试验，我们即将启动针对早期阿尔茨海默病和肌萎缩侧索硬化症（‘ALS’）的二期研究。”

We look forward to discussing how our intranasal foralumab can address unmet needs in immunotherapy and drive meaningful patient outcomes.”.

我们期待讨论我们的鼻内foralumab如何满足免疫治疗中未满足的需求，并推动有意义的患者结果。"

BIO-Europe 2025 is expected to draw over 5,700 delegates from more than 60 countries, facilitating thousands of targeted partnering meetings. Tiziana’s participation underscores its commitment to advancing novel therapies that modulate immune responses through alternative delivery routes, potentially transforming treatment paradigms for chronic neurological conditions..

BIO-Europe 2025预计将吸引来自60多个国家的超过5700名代表参加，促成数千场有针对性的合作会议。Tiziana的参与彰显了其致力于通过替代递送途径推进调节免疫反应的新型疗法，这可能为慢性神经系统疾病的治疗模式带来变革。

About Foralumab

关于Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (.

Foralumab是一种全人源抗CD3单克隆抗体，是一种生物药物候选物，已被证明在鼻内给药时能够刺激T调节细胞。目前，在一项开放标签的中等规模扩展使用（EA）项目中，已有14名非活动性继发进展型多发性硬化症（na-SPMS）患者接受了该药物的给药。

NCT06802328

NCT06802328

) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (.

）在所有患者中，6个月内观察到疾病有所改善或稳定。此外，鼻内给药的foralumab目前正在进行一项针对非活动性继发进展型多发性硬化症患者的2a期、随机、双盲、安慰剂对照、多中心、剂量范围试验研究。（

NCT06292923

NCT06292923

).

）。

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.

Foralumab是目前临床开发中唯一的全人源抗CD3单克隆抗体（mAb）。通过鼻内给予foralumab进行免疫调节，代表了治疗神经炎症和神经退行性人类疾病的新途径。

[1],[2]

[1],[2]

About Tiziana Life Sciences

关于蒂齐亚纳生命科学公司

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery.

Tiziana生命科学公司是一家临床阶段的生物制药公司，利用变革性的药物递送技术开发突破性疗法，以实现免疫治疗的替代途径。Tiziana创新的鼻腔给药方法相比静脉注射（IV）有可能在疗效以及安全性和耐受性方面提供改进。

Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications..

Tiziana的主打候选药物——鼻内给药的foralumab，是目前临床开发中唯一的全人源抗CD3单克隆抗体，在迄今为止的研究中已显示出良好的安全性和临床反应。Tiziana用于免疫治疗替代途径的技术已获得专利，还有多项申请正在审批中，预计该技术将允许广泛应用于多种研发管线。

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit

有关Tiziana Life Sciences及其创新疗法管道的更多信息，请访问

www.tizianalifesciences.com

www.tizianalifesciences.com

.

。

For further inquiries:

如需进一步查询：

Tiziana Life Sciences Ltd

蒂齐亚娜生命科学有限公司

Paul Spencer, Business Development, and Investor Relations

保罗·斯宾塞，业务发展与投资者关系

+44 (0) 207 495 2379

+44 (0) 207 495 2379

email:

电子邮件：

info@tizianalifesciences.com

info@tizianalifesciences.com

[1]

[1]

https://www.pnas.org/doi/10.1073/pnas.2220272120

https://www.pnas.org/doi/10.1073/pnas.2220272120

[2]

[2]

https://www.pnas.org/doi/10.1073/pnas.2309221120

https://www.pnas.org/doi/10.1073/pnas.2309221120